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Abstract
Background: Osteopontin (OPN) and thrombospondin-1 (TSP-1) are extracellular matrix proteins secreted by stromal
and tumor cells. These proteins appear to have a key role in the tumor microenvironment for cancer development and
metastasis. There is little information regarding the prognostic value of the combination of these two proteins in
human cancers. Our aim was to clarify clinical significance and prognostic value of each circulating protein and their
combination in primary resected non-small cell lung cancer (NSCLC) patients.
Methods: We retrospectively reviewed 171 patients with NSCLC following curative intent surgery from January to
December of 2012. Preoperative serums, demographics, clinical and pathological data and molecular profiling were
analyzed. Pre-treatment OPN and TSP-1 serum levels were measured by ELISA. Tissue protein expression in primary
tumor samples was determined by immunohistochemical analysis.
Results: OPN and TSP-1 serum levels were inversely correlated with survival rates. For each 50 units increment of
serum OPN, an increased risk of metastasis by 69 % (unadjusted HR 1.69, 95 % CI 1.12–2.56, p = 0.01) and an increased
risk of death by 95 % (unadjusted HR 1.95, 95 % CI 1.15–3.32, p = 0.01) were observed. Conversely, for each 10 units
increment in TSP-1, the risk of death was decreased by 85 % (unadjusted HR 0.15, 95 % CI 0.03–0.89; p = 0.04).
No statistically significant correlation was found between TSP-1 serum level and distant metastasis-free survival
(p = 0.2). On multivariate analysis, OPN and TSP-1 serum levels were independent prognostic factors of overall
survival (HR 1.71, 95 % CI 1.04–2.82, p = 0.04 for an increase of 50 ng/mL in OPN; HR 0.18, 95 % CI 0.04–0.87, p= 0.03 for
an increase of 10 ng/mL in TSP-1). In addition, the combination of OPN and TSP-1 serum levels remained an independent
prognostic factor for overall survival (HR 1.31, 95 % CI 1.03–1.67, p = 0.03 for an increase of 6 ng/mL in OPN/TSP-1 ratio).
Conclusions: Our results show that pre-treatment OPN and TSP-1 serum levels may reflect the aggressiveness of the
tumor and might serve as prognostic markers in patients with primary resected NSCLC.
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Background
Lung cancer, with non-small cell lung cancer (NSCLC)
constituting 85 % of cases, remains the most prevalent
and lethal cancer worldwide [1]. Surgery is the preferred
initial treatment for patients with early stage disease and
is correlated with a 5-year survival rate ranging from
70 % to 80 % in stage IA; and 30 % in stage IIIA disease
[2]. With at least two-thirds of the relapses occurring in
the 2–3 year period after initial resection [3], adjuvant
platinum-based chemotherapy has been applied as the
standard treatment for patients with early stage disease,
and its application has shown an increase of 5-year survival
rate by 4 ~ 5 % [4]. However, despite significant advances in
the molecular mechanism that underpins NSCLC, the
choice of adjuvant therapy is not guided by surrogate bio-
markers [5]. Hence, there is a critical need to identify novel
candidates for prognostic and predictive biomarkers.
Arguably, local microenvironment, alternatively known
as niche, plays crucial roles in cancer progression that
lead to dissemination of tumor cells into pre-metastatic
niches of other organs [6]. Whereas genetic and epigenetic
alterations in malignant cells have been extensively studied
during the past decades, the role of tumor microenviron-
ment has been largely overlooked [7]. It is suggested that
tumor cells do not act alone but in close interaction with
the extracellular matrix (ECM) and with non-genetically
altered stromal cells [8]. Nevertheless, the dynamic
process of dissemination and growth of cancer cells in
metastatic sites remains unclear [9]. Members of matri-
cellular proteins, such as osteopontin (OPN), throm-
bospondin (TSP), and SPARC (secreted protein acidic
and rich in cysteine), exert their functions directly by
either binding to cell surface receptors, or binding to
other ECM proteins [10]. OPN and TSP-1 have important
roles in a variety of biological processes, from cell adhe-
sion and migration, to cell survival and proliferation and
may interact with common target receptors (e.g., integrin
αvβ3) [11]. However, such proteins appear to play con-
trasting roles in tumor progression and metastasis.
TSP-1 is a 450-kDa-homotrimeric protein composed
of multiple functional domains that mediate cell-to-cell
and cell-to-matrix interactions. The diverse biological
activities of TSP-1 are mediated by its interaction with
corresponding receptors such as integrins, CD36 and
CD47, that are expressed on a variety of tumor and
stromal cells [12]. Interestingly, TSP-1 was the first
endogenous angiogenesis inhibitor to be identified [13].
Additionally, TSP-1 has been reported to inhibit tumori-
genesis and metastasis in several tumor models [14].
Lack of TSP-1 has been associated with increased
tumorigenesis; on the other hand, its over-expression or
exogenous administration inhibits tumor formation and
progression [15, 16]. To our knowledge, the role of TSP-1
in NSCLC pathogenesis has been poorly reported.
OPN is an extracellular matrix glycophosphoprotein
consisting of three isoforms, OPN-a, OPN-b, and OPN-c,
with molecular weights ranging from 41 to 75 kDa [17].
OPN contains several highly conserved structural elements
including an integrin binding RGD domain, a calcium
binding site and a heparin binding domain responsible for
CD44 receptor binding [18]. OPN exerts its functions
through direct binding to its receptors, which results in the
activation of anti-apoptotic and pro-survival pathways,
angiogenesis modulation, and ECM degradation [19]. OPN
protumoral and prometastatic activities have been dem-
onstrated in tumor animal models and in patients [20].
Although the over-expression of OPN is not unique to
NSCLC, OPN appears to play a critical role in NSCLC
carcinogenesis [21, 22]. In addition, clinical studies
have shown that circulating OPN may serve as an im-
portant biomarker in early-stage and advanced cancer
disease [23–26].
Due to contrasting effects on metastasis and angiogen-
esis, we hypothesized that the balance between circulating
OPN and TSP-1 may impact patient survival. In addition,
we supposed that the combination of circulating OPN and
TSP-1 enhanced the prognostic value of each biomarker.
The primary objective of this study was to determine the
prognostic value of pre-treatment serums levels of OPN
and TSP-1 and their combination in a cohort of primary
resected NSCLC patients. The secondary objective was to
assess the correlation between OPN and TSP-1 levels in
serum and their expression in tumoral tissue.
Methods
Ethics statement
The Gustave Roussy Cancer Center and the Marie
Lannelongue Institute Institutional Review Boards gave
approval for this study. Written informed consent was ob-
tained from included patients, and patient confidentiality
was protected throughout the study.
Patients and sample collection
Between January and December of 2012, 171 patients
with primary NSCLC who underwent curatively intended
surgical resection at Marie Lannelongue Hospital, France,
were included in this study. Patients were staged accord-
ing to the 7th edition of the IASLC/ATS/ERS classification
[27–29] and the presence of adverse features such as
visceral pleural invasion, lympho-vascular invasion and
evidence of residual tumor at the resection margin were
reviewed by a consultant histopathologist with expertise
in lung cancer. Blood samples were obtained from each
patient at baseline the day before surgery and centrifuged
within 1 h of collection at 3600 × g for 10 min. Serums
were stored at −20 °C until analysis was completed.
Samples were then aliquoted and stored at −80 °C.
Post-operative follow-ups included clinical and radiological
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examination (CT or conventional X-ray of the chest) at 3-
month intervals for the first 2 years. Tumor recurrence and
death during routine post-surgical follow-ups were re-
corded. First relapse was confirmed by pathologic diag-
nosis of the biopsy specimen.
ELISA
OPN serum levels were measured using a commercially
available enzyme test (Human OPN Quantikine ELISA
Kit, R&D Systems, Minneapolis, MN, USA) and reported
in ng/mL. All specimens were tested blinded and in du-
plicate. Serum samples from each patient were diluted
1:10 with calibrator Diluent RD5-24 and incubated in a
micro titer plate coated with OPN antibody (Human
OPN Quantikine ELISA Kit, R&D Systems, Minneapolis,
MN, USA) for 2 h at room temperature (RT). After four
washes, 200 μl of OPN conjugate (polyclonal antibody
against OPN conjugated to horseradish peroxidase) was
added to each well and incubated for 2 h at RT. Follow-
ing four washes, 200 μl of substrate (hydrogen peroxide
and chromogen) was added to each well and incubated
for 30 min at RT. The absorbance of the samples was
measured on a plate reader (Labsystems integrated EIA
Management System) at 450 nm with wave length correc-
tion at 570 nm. Standard curve and sample values were
calculated using Graph Pad Prism version 5.0 (GraphPad
Software, Inc La Jolla, CA, USA). TSP-1 serum level was
assessed using the same procedure, and each sample was
assayed using Human TSP-1 Quantikine ELISA Kit (R&D
Systems, Minneapolis, MN, USA) according to the manu-
facturer’s instructions. Controls were obtained from 20
healthy individuals (blood donors; 1:1 sex ratio).
Immunohistochemical staining
For each patient, a pathologist selected one representative
formalin-fixed, paraffin-embedded (FFPE) tumor block of
the primary tumor. Immunohistochemistry was performed
on 3 μm thick whole sections using a validated standard
protocol on a Ventana Discovery Ultra autostainer
(Ventana Medical Systems, Roche Tissue Diagnostics,
Tucson, AZ, USA). After deparaffinization and antigen
retrieval in CC1 buffer for 32 min at 98 °C, sections
were incubated with either a primary goat polyclonal
antibody (Santa Cruz Biothechnology; clone; concentra-
tion; dilution 1:100) against human OPN or a primary
mouse monoclonal antibody (Santa Cruz Biothechnol-
ogy; clone A 6.1; concentration; dilution 1:100) against
TSP-1 for 1 h at room temperature. Amplification was
achieved using an UltraView anti-rabbit HRP kit and
with diaminobenzidine as chromogen. Slides were counter-
stained with hematoxylin. A pathologist who was blinded
to the clinical data scored the immunohistochemical stain-
ing intensity. Two different scores were used to assess OPN
and TSP-1 tissue expression because of the type of staining.
OPN staining on whole slides was heterogeneous within
different areas in many tumors while TSP-1 staining was
much more homogeneous. H-score including both intensity
of staining and percentage of stained tumor cells was used
as an exploratory evaluation for OPN IHC staining. Thus,
the percentage of positive tumor cells was multiplied by the
staining intensity of tumor cell to obtain a final semi quan-
titative H score (0–300). For TSP-1, a scoring based only
on staining intensity (0 to 3) was used, similarly to intensity
scoring in the H-score. Then, the intensity of the staining
in tumor cells was scored using a semi-quantitative scale: 0
(negative), 1 (weak), 2 (moderate), and 3 (strong). The in-
tensity of the tumor infiltrating immune cells expressing
each marker was also scored using a semi-quantitative scale
from 0 (no infiltrate), 1 (mild infiltration), 2 (moderate
infiltration) to 3 (dense infiltration). Image acquisition
was performed with a Virtual Slides microscope VS120-SL
(Olympus, Tokyo, Japan), 20X air objective (0.75 NA).
Molecular profiling
Systematic molecular analysis was performed on each
tumor sample at the Genomics Platform (Gustave Roussy
Institute, Villejuif, France) to identify EGFR, HER2, KRAS,
BRAF, and PI3K mutation status. DNA was extracted
from sections of FFPE tissues. Histological examination
showed that more than 30 % of the cells were tumor cells.
Genomic DNA was extracted from 4 × 10 μm thick FFPE
block sections using the DNeasy Blood and tissue kit
(QIAGEN, Hilden, Germany) according to the manufac-
turer’s instructions. All coding sequences of exons 18 to
21 of EGFR gene (GeneBank NM005228.3); exons 2 and 3
of Kirsten rat sarcoma viral oncogene (K-RAS) gene
(NM033360-2); exon 15 of v-Raf murine sarcoma viral
oncogene homolog B1 (BRAF) gene (NM004333.4);
exons 10 and 21 of phosphatidylinositol-4,5-bispho-
sphate 3-kinase, catalytic subunit alpha (PIK3CA)
gene (NM006218.2); and exon 20 of human epidermal
growth factor receptor-2 (HER2) gene (NM 004448.2)
were analyzed. Sanger direct sequencing was performed
using Big Dye Terminator Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA) after polymerase chain
reaction amplification of targeted exons. Sequencing reac-
tions were analyzed on 48-capillary 3730 DNA Analyzer
(Applied Biosystems, Foster City, CA, USA). Sequence
reading and alignment were performed with Seq Scape
software (Applied Biosystems, Forster City, CA, USA).
Detected mutations were confirmed by an independ-
ent t test. ALK rearrangement status was determined
by fluorescent in situ hybridization assay on tumor tis-
sues using Dako Pre-treatment Kit (Dako) and Vysis
ALK Break Apart Rearrangement Probe Kit (Abott
Molecular Inc., Des Plaines, IL, USA) according to
protocols described previously [30].
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Statistical analyses
Statistical analysis was carried out using R [31]. Two sur-
vival end points were evaluated: (i) distant metastasis-free
survival (DMFS), defined as the time interval between sur-
gery and date of distant relapse or death, and (ii) overall
survival (OS), defined as the time interval between surgery
and death. Patients who were alive (OS) or without distant
relapse (DMFS) were censored at the date of last contact.
The prognostic values of serum OPN and TSP-1 were first
tested as individual variables. Then we assessed the signifi-
cance of the combination of these two variables. Hazard
ratios (HR) and 95 % confidence interval (95 % CI) were
calculated with the Cox proportional hazard regression
model. Independent clinico-pathological variables were
first analysed with univariate analysis. Variables shown in
the univariate analysis that were significantly associated
with DMFS and OS (with p < 0.2) were further analyzed in
a multivariate cox proportional hazards regression model.
Only the results of those variables that were significantly
associated with the DMFS and OS (p < 0.05) using the
stepwise variable selection method were reported. The re-
quired assumptions of proportionality in the multivariate
survival analysis were checked graphically and by Schoen-
feld’s test. DMFS and OS curves were estimated using the
Kaplan–Meier method and values between groups were
compared using the log-rank test. The association between
OPN and TSP-1 serum levels and clinico-pathological
variables were tested using Mann–Whitney U-test. Per-
centage, median, and range were reported to statistically
describe the data. The correlation between OPN serum
level and OPN tissue expression level was calculated using
the Spearman method. All the statistical tests were two
sided with a p value of 0.05.
Results
Clinicopathologic and molecular characterisitcs of
patients
Baseline characteristics of the patients are reported in
Table 1. A total of 171 subjects were identified with a
sex ratio of 2:1 (male: female) and a median age of
62 years (range 40–93). Non-smokers represented 16 %
of the population. Primary lung adenocarcinoma was the
most prevalent histotype (63 %), followed by squamous
cell carcinoma (23 %). Tumor EGFR mutation, KRAS
mutation and ALK rearrangement status were available
for 124 (72.5 %), 126 (74 %), and 167 (98 %) patients, re-
spectively. Pathological examination classified 92 % of
the patients as having stage I to IIIA, including 47 %
stage I, 21 % stage II, and 24 % stage IIIA. Thirteen
patients (8 %) were classified as having stage IIIB. The
majority (74 %) of resected specimen tumor sizes were
lower than 5.0 cm in greatest dimension (range 0.8–11.0).
All patients underwent mediastinal lymph node sampling
or dissection. Lymphatic diffusion to N1, N2 and N3
nodes was present in 16 %, 22 %, and 1 % of the patients,
respectively. No patient received neoadjuvant chemother-
apy or radiotherapy. According to clinical criteria, a total
of 48 (29 %) patients received adjuvant systemic platinum-
based chemotherapy; among which combined adjuvant
radio-chemotherapy was initiated in eight subjects (5 %).
Pre-treatment OPN and TSP-1 serum levels
Baseline serums were analyzed in 171 patients before
primary tumor removal. OPN serum levels ranged from
7 to 191 ng/ml, with a median value of 27.6 ng/ml; TSP-
1 serum levels ranged from 2946 to 30940 ng/ml, with a
median value of 14520 ng/ml. From the control group of
healthy individuals (n = 20), the median OPN and TSP-1
levels were 8.8 ng/ml [4–45], and 31 ng/ml (0–12060),
respectively. The difference in serum levels between
patients and donors was statistically significant for both
OPN and TSP-1 (p < 0.005) (Additional file 1). The asso-
ciation between clinicopathologic parameters and serum
levels is presented in Table 1 and Additional file 2.
Patients over 65 years old were more likely to have
higher levels of OPN (32.1 vs 26.3 ng/mL, respectively,
p = 0.07) and significantly lower TSP-1 serum levels
compared to younger patients (13171 vs 15057 ng/mL,
respectively, p = 0.01). No difference was found in serum
levels with regard to smoking history. We noticed an in-
crease of OPN serum level from stage I to IIIB. However,
no significant difference was observed for either OPN or
TSP-1 serum levels when the patient population was
classified into pTNM stage. OPN serum level was sig-
nificantly lower in patients with tumor size <5 cm than
in those with size ≥5 cm (p < 0.0001). In regard to patho-
logic features, neither OPN nor TSP-1 serum levels was
statistically associated with pleural involvement or
lympho-vascular invasion. OPN serum level was lower
in lung adenocarcinoma with borderline significance
(p = 0.06) whereas no statistical association was found
regarding pathological status and TSP-1. Small differences
in serum levels among the molecular status were ob-
served, however the difference did not exhibit statistical
significance. Patients with KRAS mutation tend to have
higher TSP-1 serum levels compared to those with KRAS
wild-type (15323 vs13171, respectively, p = 0.08).
Prognostic value of pre-treatment OPN and TSP-1 serum
levels
Median follow-up was 26 months (6–34 months). Uni-
variate and multivariate analysis evaluating the associ-
ation between survival and individual or combinatorial
markers are reported in Table 2 (OS) and Table 3
(DMFS). OPN serum levels as continuous variables were
significantly associated with both DMFS and OS in uni-
variate analysis (Table 2). For each 50 units increment of
serum OPN, an increased risk of metastasis by 69 %
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Table 1 Serum concentration of osteopontin (OPN) and thrombospondin-1 (TSP-1) according to baseline patients characteristics
No (%) OPN serum level TSP-1 serum level
Median (range) p value Median (range) p value
Population
Controls 20 8.8 (4–46) 31 (0–12060)
Patients 171 (100) 27.6 (7–191) <1.10e-5 14520 (2946–30940) <1.10e-5
Age, years (range)
<65 138 (81) 26.3 (7–89) 15057 (3979–30938)
≥65 33 (19) 32.1 (9–191) 0.07 13171 (2946–22011) 0.01
Sex
Female 62 (36) 26.6 (7–89) 14910 (2946–30938)
Male 109 (64) 28.2 (8–191) 0.17 13980 (3381–26077) 0.31
Smoking history
Current 87 (51) 27.9 (7–88) 15062 (2946–30938)
Former 56 (33) 27.9 (7–191) 13171 (3381–26077)
Never 27 (16) 25.0 (9–89) 0.85 14762 (5564–20468) 0.17
p TNM
IA 40 (23) 23.3 (11–89) 15270 (3381–25112)
IB 41 (24) 24.5 (7–87) 13120 (4899–26906)
IIA 21 (12) 26.7 (8–88) 12928 (7047–24731)
IIB 16 (9) 30.1 (9–78) 14440 (9043–23813)
IIIA 40 (24) 33.4 (8–148) 13639 (5450–30938)
IIIB 5 (3) 37.5 (17–191) 14816 (12862–20606)
IV 8 (5) 26.4 (9–64) 0.17 16332 (2946–22299) 0.75
Stage
I-II-IIIA 158 (92) 27.4 (7–148) 14423 (3381–30938)
IIIB 13 (8) 29.6 (9–191) 0.75 16324 (2946–22299) 0.23
Tumor size
<5 cm 125 (74) 23.3 (7–89) 14107 (2946–30938)
≥5cm 43 (26) 34.6 (9–191) <1.10e-5 15057 (5450.5-23813) 0.53
Type of resection
Wedge 22 (14) 26.11 (8–89) 13403 (2946–22299)
Lobectomy 123 (77) 26.8 (7–148) 15062.(3381–26906)
Bi-lobectomy 6 (4) 31.2 (12–191) 15804(11052–21302)
Pneumonectomy 9 (6) 38.3 (9–85) 0.17 10526 (5929–30938) 0.07
Resection margins
Clear 165 (98) 27.2 (7–191) 14519 (2946–30938)
Involved 4 (2) 54.5 (9–75) 0.26 15410 (12605–22011) 0.43
Histologic subtype
Adenocarcinoma 108 (63) 25.3 (7–148) 14799 (2946–26906)
Squamous cell carcinoma 40 (23) 32.8 (8–88) 13032 (5327–30938)
Large cell carcinoma 8 (5) 36.3 (21–72) 15720 (12480–22299)
Other 15 (9) 29.6 (9–191) 0.06 12605 (5564–24731) 0.29
Lympho-vasc. invasion
Yes 42 (26) 28.4 (9–191) 14202 (2946–24731)
No 123 (75) 27.6 (7–148) 0.47 14567 (3979–30938) 0.75
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(unadjusted HR 1.69, 95 % CI 1.12–2.56, p = 0.01) and
an increased risk of death by 95 % (unadjusted HR 1.95,
95 % CI 1.15–3.32, p = 0.01) were observed. Conversely,
TSP-1 serum levels as continuous variables were inversely
correlated with OS in univariate analysis. For each 10 units
increment in TSP-1, the risk of death was decreased by
85 % (unadjusted HR 0.15, 95 % CI 0.03–0.89; p = 0.04). No
statistically significant correlation was found between TSP-
1 serum level and DMFS (p = 0.23). The combination of
OPN and TSP-1 serum levels as continuous variable, mea-
sured as the ratio of OPN to log 10 transformation of TSP-
1, was significantly correlated with both DMFS and OS in
univariate analysis. For an increment of 6 ng/mL in this ra-
tio, a 30 % increased risk of metastasis (unadjusted HR 1.3,
95 % CI 1.06–1.59, p = 0.01) and 40 % increased risk of
death (unadjusted HR 1.4, 95 % CI 1.08–1.81, p = 0.01)
were observed. In stage I to IIIA, absence of pleural
involvement and lympho-vascular invasion were also
associated with better clinical outcome in univariate
analysis (Tables 2 and 3).
Three separate multivariate analyses that included
prognostic clinical parameters and each of the three fol-
lowing variables: OPN and TSP-1 serum levels, and their
combination were performed. As reported in Table 2,
both OPN and TSP-1 serum levels as well as their com-
bination maintained a strong prognostic value in the
multivariate model for OS (HR 1.71, 95 % CI 1.04–2.82,
p = 0.04; HR 0.18, 95 % CI 0.04–0.87, p = 0.03 and HR
1.31, 95 % CI 1.03–1.67, p = 0.03, for OPN, TSP-1 and
combination, respectively). No correlation was found
between these variables and DMFS (p > 0.05). The
other independent prognostic factor was pathological
stage. The relationship between the three markers and
survival were illustrated using Kaplan-Meier survival
curves represented in Fig. 1.
Tumor tissue expression of OPN and TSP-1
An overview of the immunohistochemical expression
patterns of OPN and TSP-1 in tumor cells and stroma is
presented in Figs. 2 and 3. The staining intensities of
OPN and TSP-1 were positive in the tumor cells and the
tumor stroma with heterogeneous expression. Thirty
eight percent of cases showed strong cytoplasmic
staining of OPN in tumor cells, while 26 % of cases
were moderate, and 36 % negative (Fig. 2a,b,c). Pa-
tients with negative stroma staining (score = 0) were
compared to the other cases (score = 1 or 2) (Fig. 2d).
Sixty-seven percent of the samples were stained posi-
tive for TSP-1, with 37 % of cases showing strong
staining and 30 % displaying moderate staining (Fig. 3a
and b). In the tumor stroma, some immune cells were
stained, prominently macrophages for OPN (Fig. 2d),
and lymphocytes and plasmocytes for TSP-1 (Fig. 3d).
There was no significant association between TSP-1
serum level and TSP-1 tissue expression level. OPN
serum level and OPN tissue expression level were
weakly correlated (Spearman coefficient correlation =
0.26) (Tables 2 and 3).
Discussion
In this study, we assessed the prognostic values of circu-
lating OPN and TSP-1 in a cohort of 171 primary oper-
able NSCLC patients. We suggested that pre-treatment
serum levels of OPN and TSP-1 might have potential
Table 1 Serum concentration of osteopontin (OPN) and thrombospondin-1 (TSP-1) according to baseline patients characteristics
(Continued)
Pleural invasion
Yes 74 (46) 28.3 (7–191) 13811 (2946–26077)
No 86 (54) 26.9 (8–89) 0.36 15247 (3381–30938) 0.27
Adjuvant treatment
Yes 48 (29) 28.1 (7–191) 14608 (5327–24731)
No 120 (71) 26.9 (8–148) 0.69 14543 (2946–30938] 0.66
EGFR status
Wild-type 112 (90) 26.8 (7–191) 13752 (2946–26906)
Mutation 12 (10) 24.6 (10–38) 0.37 15984 (10111–22165) 0.23
KRAS status
Wild-type 78 (62) 27.4 (7–188) 13171 (2946–26906)
Mutation 48 (38) 24.7 (7–191) 0.37 15323 (5327–25112) 0.08
ALK rearrangement
Yes 3 (2) 29.6 (22–64) 19801 (14519–22299)
No 164 (98) 27.2 (7–191) 0.50 14440 (2946–30938) 0.13
Rouanne et al. BMC Cancer  (2016) 16:483 Page 6 of 13
prognostic value in primary resected NSCLC patients.
Metastases represent the final step of a complex process
initiated by tumor cells from primary site to distant sites.
It is now believed that only a very small subset of circu-
lating tumor cells form macrometastasis (0.02 %);
suggesting that microenvironment of distant sites are
generally inhospitable for tumor cell growth [6, 7]. Re-
cent studies reported that tumor and stroma cells from
the primary site secrete soluble proteins including extra-
cellular matrix proteins and growth factors to prepare
metastatic niche [32, 33]. Herein, we hypothesized that
the balance between the antiangiogenic effect from TSP-1
and anti-apoptotic activity from OPN may create an
enriched tumor microenvironment that enhance cell seed-
ing and metastasis development.
Several studies have emphasized the role of OPN in
tumorigenesis, progression and metastatic dissemination
in NSCLC [34–36]. It is well known that circulating
OPN levels correlate with clinical outcomes in several
types of advanced human cancers [37–39]. Until the
recent few years, clinical implications of circulating OPN
in patients with NSCLC were not well established.
Recently, three clinical studies found that OPN plasma
levels were significantly associated with progression-free
survival and overall survival in patients with advanced
NSCLC who received either chemotherapy or radiotherapy
Table 2 Univariate and multivariate analysis of clinicopathological factors with serum osteopontin level (A), serum thrombospondin-1
level (B), serum OPN/TSP-1 ratio (C) for overall survival
Univariate analysis Multivariate analysis
HR 95 % CI p value HR 95 % CI p value
A. Factors associated with serum osteopontin level for overall survival
Osteopontin Serum levela 1.95 1.15–3.32 0.01 1.71 1.04–2.82 0.04
Stage I to IIIA vs IIIB 0.26 0.11–0.61 0.002 0.29 1.04–0.68 0.01
Pleural involvement Positive vs Negative 1.94 0.93–4.04 0.08 1.11 0.66–1.57 0.73
Lympho-vascular invasion Positive vs Negative 2.47 1.21–5.03 0.01 1.27 0.56–2.85 0.57
Adjuvant treatment No vs Yes 1.32 0.63–2.73 0.51 – – –
Age ≥65 vs <65 1.61 0.75–3.46 0.24 – – –
Gender Male vs female 1.14 0.56–2.34 0.73 – – –
Smoking history Smoker vs non-smoker 1.14 0.44–2.96 0.80 – – –
B. Factors associated with serum thrombospondin-1 level for overall survival
Thrombospondin-1 Serum levelb 0.15 0.03–0.89 0.04 0.18 0.04–0.87 0.03
Stage I to IIIA vs IIIB 0.26 0.11–0.61 0.002 0.26 0.11–0.61 0.002
Pleural involvement Positive vs Negative 1.94 0.93–4.04 0.08 1.13 0.36–1.37 0.69
Lympho-vascular invasion Positive vs Negative 2.47 1.21–5.03 0.01 1.28 0.58–2.84 0.54
Adjuvant treatment No vs Yes 1.32 0.63–2.73 0.51 – – –
Age ≥65 vs <65 1.61 0.75–3.46 0.24 – – –
Gender Male vs female 1.14 0.56–2.34 0.73 – – –
Smoking history Smoker vs non-smoker 1.14 0.44–2.96 0.80 – – –
C. Factors associated with serum osteopontin/thrombospondin-1 ratio for overall survival
OPN/TSP1 Ratioc 1.40 1.08–1.81 0.01 1.31 1.03–1.67 0.03
Stage I to IIIA vs IIIB 0.26 0.11–0.61 0.002 0.29 0.12–0.68 0.01
Pleural involvement Positive vs Negative 1.94 0.93–4.04 0.08 0.75 0.24–0.97 0.38
Lympho-vascular invasion Positive vs Negative 2.47 1.21–5.03 0.01 0.62 0.23–0.89 0.27
Adjuvant treatment No vs Yes 1.32 0.63–2.73 0.51 – – –
Age ≥65 vs <65 1.61 0.75–3.46 0.24 – – –
Gender Male vs female 1.14 0.56–2.34 0.73 – – –
Smoking history Smoker vs non-smoker 1.14 0.44–2.96 0.80 – – –
HR Hazard Ratio, 95 % CI 95 % Confidence interval
afor an increment in OPN of 50 ng/mL
bfor an increment in TSP-1 of 10 ng/mL in log10 scale
cfor an increment of 6 ng/mL in the ratio OPN/log10 (TSP1)
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[23, 25, 40]. Takenaka et al. [41] found that OPN serum
level was an unfavorable prognostic predictor not only for
patients with advanced NSCLC but also for patients with
stage I disease. Similarly, we noted that an increase in
serum OPN level was associated with poor prognosis
according to survival outcomes in primary resected
NSCLC patients.
In our study, we reported a median serum OPN level
of 27.6 ng/ml (7–191 ng/ml), which is comparable to
results from previous series in serum [41] or plasma
[26]. The significant difference between OPN serum
levels in healthy individuals versus NSCLC patients
promotes the potential diagnostic relevance of OPN as
a biomarker for NSCLC. Furthermore, we found that
OPN serum levels increased significantly according to
tumor size, suggesting that its production by tumor
cells prevailed. Interestingly, Blasberg et al. [26] re-
ported that baseline OPN plasma levels were reduced
after primary resection of NSCLC tumor. They also
demonstrated that OPN plasma levels had risen when
the patients relapsed. Contrary to other reports, no
correlation was found between OPN tumor tissue ex-
pression in primary tumor and clinical outcomes. In
our study, immunohistochemical staining was per-
formed on whole tumor sections instead of tissue
microarray, which avoided bias interpretation due to
Table 3 Univariate and multivariate analysis of clinicopathological factors with serum osteopontin level (A), serum thrombospondin-1
level (B), serum OPN/TSP-1 ratio (C) for distant metastasis-free survival (DMFS)
Univariate analysis Multivariate analysis
HR 95 % CI p value HR 95 % CI p value
A. Factors associated with serum osteopontin level for distant metastasis-free survival
Osteopontin Serum levela 1.69 1.12–2.56 0.01 1.35 0.93–1.97 0.12
Stage I to IIIA vs IIIB 0.23 0.12–0.44 <0.0001 0.31 0.15–0.63 0.001
Pleural involvement Positive vs Negative 2.58 1.50–4.43 <0.001 1.91 1.07–3.40 0.03
Lympho-vascular invasion Positive vs Negative 2.33 1.37–3.87 0.002 1.80 1.02–3.17 0.04
Adjuvant treatment No vs Yes 1.20 0.70–2.04 0.54 – – –
Age ≥65 vs <65 1.05 0.56–1.97 0.91 – – –
Gender Male vs female 0.97 0.59–1.61 0.92 – – –
Smoking history Smoker vs non-smoker 1 0.51–1.97 1 – – –
B. Factors associated with serum thrombospondin-1 level for distant metastasis-free survival
Thrombospondin-1 Serum levelb 0.39 0.10–1.45 0.23 – – –
Stage I to IIIA vs IIIB 0.23 0.12–0.44 <0.0001 0.29 0.14–0.58 0.001
Pleural involvement Positive vs Negative 2.58 1.50–4.43 <0.001 1.91 1.07–3.41 0.03
Lympho-vascular invasion Positive vs Negative 2.33 1.37–3.87 0.002 1.79 1.01–3.14 0.04
Adjuvant treatment No vs Yes 1.20 0.70–2.04 0.54 – – –
Age ≥65 vs <65 1.05 0.56–1.97 0.91 – – –
Gender Male vs female 0.97 0.59–1.61 0.92 – – –
Smoking history Smoker vs non-smoker 1 0.51–1.97 1 – – –
C. Factors associated with serum osteopontin/thrombospondin-1 ratio for distant metastasis-free survival
OPN/TSP1 Ratioc 1.31 1.06–1.59 0.01 1.16 0.97–1.40 0.11
Stage I to IIIA vs IIIB 0.23 0.12–0.44 <0.0001 0.31 0.15–0.63 0.001
Pleural involvement Positive vs Negative 2.58 1.50–4.43 <0.001 1.90 1.07–3.40 0.03
Lympho-vascular invasion Positive vs Negative 2.33 1.37–3.87 0.002 1.80 1.02–3.17 0.04
Adjuvant treatment No vs Yes 1.20 0.70–2.04 0.54 – – –
Age ≥65 vs <65 1.05 0.56–1.97 0.91 – – –
Gender Male vs female 0.97 0.59–1.61 0.92 – – –
Smoking history Smoker vs non-smoker 1 0.51–1.97 1 – – –
HR Hazard Ratio, 95 % CI 95 % Confidence interval
afor an increment in OPN of 50 ng/mL
bfor an increment in TSP-1 of 10 ng/mL in log10 scale
cfor an increment of 6 ng/mL in the ratio OPN/log10 (TSP1)
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intratumoral heterogeneity. Other possible explanations for
the contradicting results could be that different antibodies,
immunohistochemical staining techniques and scoring sys-
tems were used. Lack of correlation between serum levels
and tissue expression may be explained by the variability of
OPN production from normal and tumor cells.
Our study showed that an increase in serum TSP-1
level was associated with good prognosis according to
survival analysis. Arguably, several studies have reported
the ability of TSP-1 to inhibit tumor angiogenesis.
Yamaguchi et al. demonstrated that reduced expression




Fig. 1 Estimated Kaplan-Meier curves for distant metastasis-free and overall survival categorized by the serum level of (a) osteopontin,
(b) thrombospondin-1 and (c) their combination. The osteopontin high group was defined as the top 20 % patient population with
the highest values in osteopontin level and the osteopontin low group represented the rest of the population. Thrombospondin-1
low group was defined as the top 10 % patient population with the lowest values in thrombospondin-1 level and thrombospondin-1
high group represented the rest of the population
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patients [42]. Indeed, strong evidence suggests an in-
hibitory role of TSP-1 in cancer cell proliferation and
metastasis [43]. Inhibitory effect of TSP-1 in cancer cell
proliferation and metastasis comes from studies in
human lung cancer cell lines, whereas an inverse cor-
relation has been reported between TSP-1 messenger
RNA, protein expression and malignant progression
[44]. Furthermore, transfection studies in breast cancer
cell lines have demonstrated that production of TSP-1
in tumor cell exerts an inhibitory effect on tumor pro-
gression [45].
We also found a median TSP-1 serum level of
14520 ng/ml (2946–30940 ng/ml), which was much
higher compare to OPN serum levels in the same cohort.
Significant difference was observed between patients and
controls (p < 0.001). Compared to OPN, we found an in-
verse correlation between TSP-1 serum level and clinical
outcomes, suggesting a protective role for TSP-1. Surpris-
ingly, we found a statistically significant association
between age and TSP-1 serum level, suggesting that
people under 65 years old secreted more TSP-1.
Nevertheless, age was not identified as prognostic factor
in univariate and multivariate analyses. Similarly, tumor
expression was heterogeneous with variable staining in-
tensity among tumor and stroma cells, and no correl-
ation was observed with patients outcomes. Secretion
from a variety of normal and tumor cell types may ex-
plain the absence of correlation between serum levels
and tissue expression.
To our knowledge, this is the first study investigating
the prognostic value of circulating OPN and TSP-1 in
primary resected NSCLC patients. One of the major
strength of our study was to assess simultaneously pre-
treatment circulating OPN and TSP-1 in the same co-
hort of NSCLC patients who underwent curative intent
surgery. Hence, combining OPN and TSP-1 serum levels
may enhance the prognostic value of each biomarker
and more accurately reflect the aggressiveness of the tumor.
Nevertheless, our study suffers from several limitations.
First, this is a retrospective serie with a small sample size
and a statistical power limited by short-term follow-up. In
addition, the potential use of tyrosine kinase inhibitors in
Fig. 2 Representative immunohistochemical staining showing positive (a =moderate, b = strong), negative (c) osteopontin tumor cells expression
and positive (d) stroma staining
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12 (7 %) patients with targetable genomic alterations (i.e.
activating EGFR mutations and ALK translocation) was not
assessed in the univariate and multivariate analysis for over-
all survival. Second, biology of matricellular proteins is
complex. Indeed, intracellular forms of OPN and TSP-1
probably mediate different metastatic activity than exogen-
ous proteins. To understand the role matricellular proteins
play within the tumor microenvironment, it is also import-
ant to decipher OPN and TSP-1 interaction networks oc-
curring between tumor cells and stroma. Finally, better
understanding of cell signaling mechanisms induced by
OPN and TSP-1 is essential to deeply explore the cancer
pathways activated among tumor cells.
Conclusion
Our results show that pre-treatment OPN and TSP-1
serum levels may reflect the aggressiveness of the
tumor and might serve as prognostic markers in pa-
tients with primary resected NSCLC. This study pro-
vides further support of the importance of tumor
microenvironment in the biology of NSCLC.
Undoubtedly, better understanding of the cellular con-
stituents of tumors and interactions between malig-
nant and stromal cells may help develop next
generation innovative cancer therapeutics.
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